NETRF Board of Scientific Advisors

The Board of Scientific Advisors provides the scientific direction to the Neuroendocrine Tumor Research Foundation (NETRF) by offering programmatic advice, conducting peer-review of grant proposals to identify the best research, and serving as leaders in the field. The Board of Scientific Advisors comprises highly distinguished scientific and medical leaders who share a commitment to discovering a cure for neuroendocrine cancer. All members of the Board of Scientific Advisors are recognized experts in experimental and medical research, published authors in the top peer-reviewed medical journals, and leaders of collaborative research projects at top-ranked universities and institutes.

Board of Scientific Advisors

Dawn E. Quelle, PhD

CO-CHAIR
Professor, Neuroscience and Pharmacology; Leader, Cancer Genes and Pathways Program, Holden Comprehensive Cancer Center; University of Iowa, Carver College of Medicine

Education: The Pennsylvania State University (PhD) 
Fellowships: The Pennsylvania State University, St. Jude Children’s Research Hospital

Chrissie Thirlwell, MD, PhD

CO-CHAIR

Head of Bristol Medical School, University of Bristol, UK; Faculty of Health and Life Sciences; Consultant Medical Oncologist UHBW and North Bristol NHS Trust

Education: University College London (MD); University of London (PhD)
Post-Graduate Training: St. Bartholomew’s Hospital, Chelsea and Westminster, Charing Cross, Hammersmith and University College London Hospitals

James A. Bibb, PhD

Professor and Chair, Department of Translational Neurosciences, University of Arizona College of Medicine in Phoenix

Education: UT Southwestern Medical Center at Dallas

Lisa Bodei, MD, PhD

Professor of Radiology at Weill Cornell Medical College and Attending Physician and Director of Targeted Radionuclide Therapy, Molecular Imaging and Therapy Service at Memorial Sloan Kettering Cancer Center

Board Certification: Nuclear Medicine
Education: University of Pisa (MD); University of Groningen (PhD)
Residency: University of Pisa (Italy)
Fellowship: European Institute of Oncology (Italy)

Daniel Chung, MD

Professor of Medicine, Harvard Medical School; Director, Hi-Risk Gastrointestinal Cancer Clinic, Massachusetts General Hospital

Board Certification: Gastroenterology
Education: Harvard Medical School (MD)
Residency: Massachusetts General Hospital
Fellowship: Massachusetts General Hospital

Jennifer R. Eads, MD

Associate Professor of Clinical Medicine (Hematology-Oncology); Physician Lead for GI Clinical Research; Director, National Clinical Trials Network, Abramson Cancer Center; Director, Neuroendocrine Tumor Program, Division of Hematology and Oncology, University of Pennsylvania, Perelman Center for Advanced Medicine

Board Certification: Internal Medicine and Medical Oncology
Education: Tufts University School of Medicine (MD)
Residency: University Hospitals Case Medical Center
Fellowships: University Hospitals Case Medical Center

George Fisher, MD, PhD

Colleen Haas Chair in the School of Medicine, Stanford Medical School

Board Certification: Medical Oncology
Education: Stanford University (MD and PhD)
Residency: Stanford University Medical Center
Fellowships: Stanford University Medical Center

Daniel M. Halperin, MD

Associate Professor, Gastrointestinal Medical Oncology and Clinical Medical Director, Gastrointestinal Center, MD Anderson Cancer Center

Board Certification: Medical Oncology and Internal Medicine
Education: Weill Cornell Medical College (MD)
Residency: Brigham and Women’s Hospital
Fellowship: MD Anderson Cancer Center

John D. Minna, MD

Director, Hamon Center for Therapeutic Oncology Research; Professor of Internal Medicine & Pharmacology, University of Texas Southwestern Medical Center; Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology and Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research

Education: Stanford University Medical Center (MD) 
Residency: Massachusetts General Hospital
Fellowship: National Institutes of Health 

Anil Rustgi, MD

Herbert and Florence Irving Professor of Medicine; Director, Herbert Irving Comprehensive Cancer Center at Columbia University; Associate Dean of Oncology, Vagelos College of Physicians and Surgeons; Chief, Cancer Services, New York Presbyterian Hospital/Columbia University Irving Medical Center campus

Board Certification: Internal Medicine
Education: Yale University (MD)
Residency: Harvard Medical School, Beth Israel Deaconess Medical Center
Fellowship: Massachusetts General Hospital

Ramesh Shivdasani, MD, PhD

Professor of Medicine, Harvard Medical School; Deputy Director, Dana-Farber/Harvard Cancer Center

Board Certification: Medical Oncology
Education: University of Michigan (MD and PhD)
Fellowship: Dana-Farber Cancer Institute
Residency: Brigham and Women’s Hospital

Emeritus Members

  • Todd Golub, MD, Chief Scientific Officer, Broad Institute
  • Arnold Levine, PhD, Simons Center for Systems Biology at the Institute for Advanced Study
  • Thomas J. Lynch Jr., MD, Director, Fred Hutchinson Cancer Research Center
  • William Sellers, MD, Broad Institute
  • Evan Vosburgh, MD, Yale University School of Medicine